Perrigo announced that it has initiated market launch and made its first shipments of minoxidil 5% foam, which is a generic version of Rogaine 5% foam hair regrowth treatment, to its retail and wholesale customers. Minoxidil 5% foam is marketed under store- or own-label brands.

Perrigo on Thursday named Bruce Johnson to VP consumer healthcare research and development. Johnson will lead new product development for the supplier in the U.S. market.

Perrigo last week announced that it has received final Food and Drug Administration approval for its generic prescription allergy remedy desloratadine 5 mg, the generic equivalent to Schering-Plough's Clarinex.

Perrigo on Monday named Christopher Roop to the post of VP corporate development.

Drug maker Perrigo has filed for regulatory approval of a generic topical drug for treating testosterone deficiency, prompting a patent infringement suit from the branded version's manufacturer.

Perrigo this summer developed a healthcare professional outreach strategy, educating pediatricians, for example, around the company’s new infants’ and children’s acetaminophen dosing and packaging changes.

Perrigo on Wednesday announced that its closing date to complete the acquisition of Paddock Labs — a generic pharmaceutical and specialty over-the-counter products manufacturer — has been delayed by an extended Federal Trade Commission review.

The Food and Drug Administration has approved a generic version of Rogaine made by Perrigo, the drug maker said.

Perrigo on Wednesday named Tony Schott VP diabetes care for the consumer healthcare division.

Perrigo on Friday named Lynden Johncock to the post of trade promotion manager with the sales department. In this combined marketing and sales role, Johncock will act as a liaison between customers and Perrigo to ensure effective exchange of ideas for business and product line growth.

Perrigo will buy Paddock Labs for more than half a billion dollars, Perrigo said Thursday.